Cyclooxygenase-2 expression in epithelial neoplasms and its relevance as a targeted therapy in dogs

Cunha, Rúbia Monteiro de Castro; Horta, R.S.; Lavalle, Gleidice Eunice; Araújo, Roberto Baracat de

doi:10.1590/0103-8478cr20150794

Cited by 5 publications

(5 citation statements)

References 8 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tumors expressing Cox-2 can be targeted for treatment with Cox-2 inhibitors, such as meloxicam or piroxicam, which have been shown to inhibit cell proliferation and angiogenesis [96,97]. In both human [98][99][100] and veterinary medicine [101,102], targeting Cox-2 with selective Cox-2 inhibitors has been helpful, or could be a promising therapeutic approach for SCC treatment. Prior determination of Cox-2 expression in tumors is crucial for successful treatment with these inhibitors [103,104].…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas

Luís,

Files,

Cardoso

et al. 2024

CIMB

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) stands as the second most prevalent skin cancer in dogs, primarily attributed to UV radiation exposure. Affected areas typically include regions with sparse hair and pale or depigmented skin. The significance of spontaneous canine cutaneous SCC as a model for its human counterpart is underscored by its resemblance. This study assesses the expression of key markers—Epidermal Growth Factor Receptor (EGFR), Cyclooxygenase-2 (Cox-2), and Ki-67—in canine cutaneous SCC. Our objective is to investigate the association between their expression levels and classical clinicopathological parameters, unraveling the intricate relationships among these molecular markers. In our retrospective analysis of 37 cases, EGFR overexpression manifested in 43.2% of cases, while Cox-2 exhibited overexpression in 97.3%. The EGFR, Cox-2 overexpression, and Ki-67 proliferation indices, estimated through immunohistochemistry, displayed a significant association with the histological grade, but only EGFR labeling is associated with the presence of lymphovascular emboli. The Ki-67 labeling index expression exhibited an association with EGFR and Cox-2. These findings propose that EGFR, Cox-2, and Ki-67 hold promise as valuable markers in canine SCC. EGFR, Cox-2, and Ki-67 may serve as indicators of disease progression, offering insights into the malignancy of a lesion. The implications extend to the potential therapeutic targeting of EGFR and Cox-2 in managing canine SCC. Further exploration of these insights is warranted due to their translational relevance and the development of targeted interventions in the context of canine SCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas

Luís,

Files,

Cardoso

et al. 2024

CIMB

View full text Add to dashboard Cite

show abstract

“…2021 potencializar os efeitos da quimioterapia antineoplásica (FINOTELLO et al, 2017). Esses medicamentos são indicados para o tratamento do câncer, pois exerceram efeitos preventivos e terapêuticos em modelos de neoplasia canina espontânea e experimental (CUNHA et al, 2016;FRANZONI et al, 2017).…”

Section: Discussionunclassified

Efeito modulador do Previcox® sobre a ação carcinogênica da doxorrubicina por meio do teste de tumores epiteliais (ETT) em Drosophila melanogaster

Bontempo

Orsolin

2021

cmbio

View full text Add to dashboard Cite

Introdução: a superexpressão da COX-2 relaciona-se com o aumento da produção de fatores de crescimento vascular e como consequência, com o desenvolvimento tumoral. O Firocoxib é um anti-inflamatório não esteroidal utilizado para inflamação associada à osteoartrite em cães. É o inibidor mais seletivo da COX-2, reduzindo eficientemente a ação desta enzima. Estudos indicam os benefícios do Firocoxib na terapia antineoplásica. Objetivo: este trabalho objetivou avaliar o efeito modulador do Firocoxib sobre a ação da doxorrubicina (DXR) por meio do teste de tumores epiteliais (ETT) em Drosophila melanogaster. Metodologia: foram preparadas três concentrações de Firocoxib: 2,5; 5 e 10 mg/mL, utilizadas isoladamente e em associação à doxorrubicina. O tratamento ocorreu com larvas de D. melanogaster descendentes do cruzamento de fêmeas wts/TM3 com machos mwh/mwh. Resultados: os resultados sugerem que o Firocoxib possui atividade moduladora sobre a ação carcinogênica da DXR, pois houve redução significativa nas frequências tumorais dos indivíduos tratados com diferentes concentrações de Firocoxib em cotratamento com a doxorrubicina quando comparadas à frequência tumoral do controle positivo. Conclusão: conclui-se que, nas presentes condições experimentais, o Firocoxib reduziu a frequência de tumores induzidos pela doxorrubicina em D. melanogaster.

show abstract

“…Increased numbers of mitotic figures, in deeper layers of the primary tumor, was correlated to Ki-67 immunoexpression, as expected. Intestinal carcinoma tends to become more malignant and invasive with time and local inflammatory stimulus (Head et al, 2002), which in this case could have led to an increase of affected layers (until the muscle tunica), but also to an increased capability to develop metastasis, which can be evidenced by increased COX-2 expression in metastatic foci, especially in the liver when compared to the primary mass (Cunha et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

“…In the dog, increases of COX-2 expression has been observed in tumors of various origins (Doré, 2011), including intestinal neoplasm (McEntee et al, 2002). In epithelial tumors it can be an effective tool for prognosis establishing (Cunha et al, 2016), and as a predictive factor for the use of selective COX-2 inhibitors in adjuvant treatments (Lavalle et al, 2009;Cunha et al, 2016). The high expression of COX-2 documented in metastatic cells of this cancer indicates that such treatment could be interesting in this case.…”

Section: Discussionmentioning

confidence: 99%

Tubulopapillary rectal adenocarcinoma in dog: clinical, surgical, pathological and immunophenotypical aspects: case report

Oliveira

Flecher

Horta

et al. 2018

Arq. Bras. Med. Vet. Zootec.

View full text Add to dashboard Cite

Intestinal carcinomas are rare in dogs. The prognosis and survival time are dependent of the histological type, the invasion of the intestinal wall by the malignant cells and the ability of primary neoplasm to produce metastasis. This study reports a case of a Yorkshire dog that developed a rectal tubulopapillary adenocarcinoma progressing to a peritoneal carcinomatosis and multiple metastasis in large intestines, bladder, kidney, iliac lymph node, liver and lungs, six months after transanal surgical resection of the primary rectal neoplasm. Clinical, surgical, pathological and immunophenotypic findings are described. COX-2 imunohistochemical score was higher in hepatic metastasis (score 9) than in the primary tumour (score 6), and the growth fraction (Ki-67) observed was of 49.2% in the rectal neoplasm.

show abstract

Cyclooxygenase-2 expression in epithelial neoplasms and its relevance as a targeted therapy in dogs

Abstract: Targeted therapy of neoplasms is an emergent approach in human and veterinary medicine. Cyclooxygenase (COX) is a class of catalytic enzymes related to the formation of inflammatory mediators. COX-2 is expressed constitutively in

Cited by 5 publications

References 8 publications

Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas

Immunohistochemical Expression Levels of Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Ki-67 in Canine Cutaneous Squamous Cell Carcinomas

Efeito modulador do Previcox® sobre a ação carcinogênica da doxorrubicina por meio do teste de tumores epiteliais (ETT) em Drosophila melanogaster

Tubulopapillary rectal adenocarcinoma in dog: clinical, surgical, pathological and immunophenotypical aspects: case report

Contact Info

Product

Resources

About